Recent Posts

Bayer, J&J’s drug Xarelto fails trial by ‘Mariner’

Bloomberg Bayer AG and Johnson & Johnson’s blood-thinning drug Xarelto didn’t prevent clotting in high-risk patients after they were released from the hospital, a setback for one of the manufacturers’ best-selling drugs. About 12,000 medically ill patients at increased risk of blood clotting took part in the trial, known as the Mariner study. The results were presented at the European ...

Read More »

Musk’s brazen gambit collapsed as investor support withered

Bloomberg Elon Musk’s stunning tweet that he wanted to take Tesla Inc. private and had funding secured was a classic Musk moonshot — given credibility only by the sense that if anyone could possibly pull such a brazen feat, he was the guy. The initial scoffing after that August 7 post gave way to hiring of bankers to a board ...

Read More »

China’s tech growth is getting more expensive

China’s consumer growth is a key plank underpinning the investment thesis for many of the country’s big technology companies. But the torrent of revenue from domestic customers is getting expe- nsive, forcing the likes of Tencent Holdings Ltd, Alibaba Group Holding Ltd and Sina Corp to pony up more cash just to keep the numbers humming along at the accustomed ...

Read More »
Send this to a friend